• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/8/21 8:40:28 AM ET
    $PAIC
    Business Services
    Finance
    Get the next $PAIC alert in real time by email
    SC 13G/A 1 d78732dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Petra Acquisition, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    716421201

    (CUSIP Number)

    December 31, 2020

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐

    Rule 13d-1(b)

     

      ☒

    Rule 13d-1(c)

     

      ☐

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    (Continued on the Following Pages)

    (Page 1 of 8 Pages)

     


    Page 2 of 8

     

    CUSIP No. 716421201

     

      1.    

      NAMES OF REPORTING PERSONS

     

      LINDEN CAPITAL L.P.

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☒        (b)  ☐

     

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Bermuda

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5.     

      SOLE VOTING POWER

     

      0

       6.   

      SHARED VOTING POWER

     

      614,101

       7.   

      SOLE DISPOSITIVE POWER

     

      0

       8.   

      SHARED DISPOSITIVE POWER

     

      614,101

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      614,101

    10.  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      6.6%

    12.  

      TYPE OF REPORTING PERSON

     

      PN


    Page 3 of 8

     

    CUSIP No. 716421201

     

      1.    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      LINDEN GP LLC

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☒        (b)  ☐

     

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5.     

      SOLE VOTING POWER

     

      0

       6.   

      SHARED VOTING POWER

     

      614,101

       7.   

      SOLE DISPOSITIVE POWER

     

      0

       8.   

      SHARED DISPOSITIVE POWER

     

      614,101

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      614,101

    10.  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      6.6%

    12.  

      TYPE OF REPORTING PERSON

     

      HC


    Page 4 of 8

     

    CUSIP No. 716421201

     

      1.    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      LINDEN ADVISORS LP

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☒        (b)  ☐

     

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5.     

      SOLE VOTING POWER

     

      0

       6.   

      SHARED VOTING POWER

     

      679,000

       7.   

      SOLE DISPOSITIVE POWER

     

      0

       8.   

      SHARED DISPOSITIVE POWER

     

      679,000

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      679,000

    10.  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      7.3%

    12.  

      TYPE OF REPORTING PERSON

     

      IA, PN


    Page 5 of 8

     

    CUSIP No. 716421201

     

      1.    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      SIU MIN WONG

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☒        (b)  ☐

     

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      China (Hong Kong) and USA

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5.     

      SOLE VOTING POWER

     

      0

       6.   

      SHARED VOTING POWER

     

      679,000

       7.   

      SOLE DISPOSITIVE POWER

     

      0

       8.   

      SHARED DISPOSITIVE POWER

     

      679,000

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      679,000

    10.  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      7.3%

    12.  

      TYPE OF REPORTING PERSON

     

      IN, HC


    Page 6 of 8

     

    This Amendment No. 1 (“Amendment No. 1”) is filed pursuant to Rule 13d-2(b) promulgated under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock, par value $0.001 per share (the “Shares”), of Petra Acquisition, Inc. (the “Issuer”) beneficially owned by the Reporting Persons specified herein as of December 31, 2020, and amends and supplements the Schedule 13G filed October 16, 2020 (collectively, the “Schedule 13G”). Except as set forth herein, the Schedule 13G is unmodified.

    The names of the persons filing this statement on Amendment No. 1 are: Linden Capital L.P., a Bermuda limited partnership (“Linden Capital”), Linden Advisors LP, a Delaware limited partnership (“Linden Advisors”), Linden GP LLC, a Delaware limited liability company (“Linden GP”), and Mr. Siu Min (Joe) Wong (“Mr. Wong,” and collectively, the “Reporting Persons”).

     

    Item 4.

    Ownership:

     

    Item 4(a)

    Amount Beneficially Owned:

    As of December 31, 2020, each of Linden Advisors and Mr. Wong may be deemed the beneficial owner of 679,000 Shares. This amount consists of 614,101 Shares held by Linden Capital and 64,899 Shares held by separately managed accounts. As of December 31, 2020, each of Linden GP and Linden Capital may be deemed the beneficial owner of the 614,101 Shares held by Linden Capital.

     

    Item 4(b)

    Percent of Class:

    As of December 31, 2020, each of Linden Advisors and Mr. Wong may be deemed the beneficial owner of approximately 7.3% of Shares outstanding, and each of Linden GP and Linden Capital may be deemed the beneficial owner of approximately 6.6% of Shares outstanding. These percentages are based on 9,290,651 Shares outstanding based on disclosures by the issuer in its quarterly report on Form 10-Q filed on November 16, 2020.

     

    Item 4(c)

    Number of Shares as to which such person has:

    As of December 31, 2020:

    Linden Capital and Linden GP:

     

    (i) Sole power to vote or direct the vote:

         0  

    (ii) Shared power to vote or direct the vote:

         614,101  

    (iii) Sole power to dispose or direct the disposition of:

         0  

    (iv) Shared power to dispose or direct the disposition of:

         614,101  


    Page 7 of 8

     

    Linden Advisors and Mr. Wong:

     

    (i) Sole power to vote or direct the vote:

         0  

    (ii) Shared power to vote or direct the vote:

         679,000  

    (iii) Sole power to dispose or direct the disposition of:

         0  

    (iv) Shared power to dispose or direct the disposition of:

         679,000  

     

    Item 5.

    Ownership of Five Percent or Less of a Class:

    Not applicable.

     

    Item 10.

    Certification:

    By signing below, the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Sec. 240.14a-11.


    Page 8 of 8

     

    SIGNATURES

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

    Dated: February 04, 2021

     

      LINDEN CAPITAL L.P.
        By:   Linden GP LLC, its general partner
                   By:  

    /S/ Saul Ahn

            Saul Ahn,
            Authorized Signatory
      LINDEN GP LLC
      By:  

    /S/ Saul Ahn

          Saul Ahn,
          Authorized Signatory
      LINDEN ADVISORS LP
      By:  

    /S/ Saul Ahn

          Saul Ahn,
          General Counsel
      SIU MIN WONG
      By:  

    /S/ Saul Ahn

        Saul Ahn, Attorney-in-Fact for Siu Min Wong**

     

    **

    Duly authorized under Siu Min Wong’s Power of Attorney, dated June 10, 2019, incorporated herein by reference to Exhibit B of the statement on Schedule 13G filed by Linden Capital L.P. on June 19, 2019 in respect of its holdings in Haymaker Acquisition Corp II.

    Get the next $PAIC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PAIC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PAIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Feis Lawrence disposed of $7,465,890 worth of shares (731,950 units at $10.20)

      4 - Petra Acquisition Inc. (0001810560) (Issuer)

      1/11/22 3:59:54 PM ET
      $PAIC
      Business Services
      Finance
    • SEC Form 3: New insider Feis Lawrence claimed ownership of 746,491 shares

      3 - Petra Acquisition Inc. (0001810560) (Issuer)

      11/2/21 2:39:14 PM ET
      $PAIC
      Business Services
      Finance
    • SEC Form 4: Glazer Capital, Llc sold $6,597,824 worth of Common stock (654,546 units at $10.08)

      4 - Petra Acquisition Inc. (0001810560) (Issuer)

      9/23/21 4:21:06 PM ET
      $PAIC
      Business Services
      Finance

    $PAIC
    SEC Filings

    See more
    • Petra Acquisition, Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Unregistered Sales of Equity Securities, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Change in Shell Company Status

      8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

      1/14/22 4:28:56 PM ET
      $PAIC
      Business Services
      Finance
    • Petra Acquisition, Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

      1/13/22 3:53:16 PM ET
      $PAIC
      Business Services
      Finance
    • Petra Acquisition, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

      1/12/22 4:49:37 PM ET
      $PAIC
      Business Services
      Finance

    $PAIC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Revelation Biosciences Inc. Receives Approval to Initiate Phase 2b Viral Challenge Study of REVTx 99, an Experimental Prophylactic Treatment for the Prevention of Respiratory Viral Infections

      - Phase 2b study will investigate the efficacy of REVTx-99 on viral load and patient-reported flu symptoms- - Top-line data anticipated in the second quarter of 2022 - SAN DIEGO, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (Revelation), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, announced today it has received approval from the Federal Agency for Medicines and Health Products (FAMHP) and the local Committee of Medical Ethics in Belgium to conduct a Phase 2b influenza viral challenge study. The Phase 2b, randomized, double-blind, influenza viral challenge study (RV

      9/28/21 9:00:00 AM ET
      $PAIC
      Business Services
      Finance
    • Revelation Biosciences, Inc., a Life Sciences Company Developing Therapeutics and Diagnostics for Respiratory Viral Infections, Including COVID-19, to Become Publicly Traded Through a Merger with Petra Acquisition, Inc.

      Revelation's lead product candidate REVTx-99 has potential, through innate immune system stimulation, to broadly prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2 including its variants, influenza A and B, parainfluenza, rhinovirus, and respiratory syncytial virus (RSV) Combined company expected to have a post-transaction pro forma total enterprise value of approximately $128 million Merger expected to close in Q4 2021, and combined company will be listed on NASDAQ under the ticker symbol "REVB" Revelation and Petra Acquisition will host a joint investor conference call and webcast to discuss the proposed transaction on August 30, 2021 at 4:30 p.m

      8/30/21 6:00:00 AM ET
      $PAIC
      Business Services
      Finance
    • PETRA ACQUISITION, INC. RECEIVES EXPECTED NASDAQ NOTIFICATION REGARDING DELAYED FORM 10-Q

      New York, NY, June 01, 2021 (GLOBE NEWSWIRE) -- Petra Acquisition, Inc. (NASDAQ:PAIC) (the "Company"), a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, announced that on May 28, 2021, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") advising that because the Company failed to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2021 (the "Form 10-Q"), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"). Nasdaq has inform

      6/1/21 4:30:00 PM ET
      $PAIC
      Business Services
      Finance

    $PAIC
    Financials

    Live finance-specific insights

    See more
    • Revelation Biosciences, Inc., a Life Sciences Company Developing Therapeutics and Diagnostics for Respiratory Viral Infections, Including COVID-19, to Become Publicly Traded Through a Merger with Petra Acquisition, Inc.

      Revelation's lead product candidate REVTx-99 has potential, through innate immune system stimulation, to broadly prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2 including its variants, influenza A and B, parainfluenza, rhinovirus, and respiratory syncytial virus (RSV) Combined company expected to have a post-transaction pro forma total enterprise value of approximately $128 million Merger expected to close in Q4 2021, and combined company will be listed on NASDAQ under the ticker symbol "REVB" Revelation and Petra Acquisition will host a joint investor conference call and webcast to discuss the proposed transaction on August 30, 2021 at 4:30 p.m

      8/30/21 6:00:00 AM ET
      $PAIC
      Business Services
      Finance

    $PAIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Petra Acquisition, Inc. (Amendment)

      SC 13G/A - Petra Acquisition Inc. (0001810560) (Subject)

      1/11/22 3:34:57 PM ET
      $PAIC
      Business Services
      Finance
    • SEC Form SC 13G/A filed by Petra Acquisition, Inc. (Amendment)

      SC 13G/A - Petra Acquisition Inc. (0001810560) (Subject)

      10/12/21 4:02:40 PM ET
      $PAIC
      Business Services
      Finance
    • SEC Form SC 13G/A filed by Petra Acquisition, Inc. (Amendment)

      SC 13G/A - Petra Acquisition Inc. (0001810560) (Subject)

      10/12/21 10:33:03 AM ET
      $PAIC
      Business Services
      Finance